BMY vs PFE
Bristol Myers Squibb Co. and Pfizer Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | BMY | PFE |
|---|---|---|
| Revenue | $48.2B | $62.6B |
| Net income | $7.1B | $7.8B |
| Gross margin | 71.1% | 74.3% |
| Net margin | 14.6% | 12.5% |
| Return on equity | 40.5% | 8.9% |
| Diluted EPS | $3.46 | $1.36 |
| Dividend / share | $2.49 | $1.72 |
| Payout ratio | 71.5% | · |
| Free cash flow | $12.8B | $9.1B |
| Equity | $18.5B | $86.5B |
| Net debt / equity | 1.87× | 0.73× |
| Current ratio | 1.26× | 1.16× |
| Revenue CAGR 5y | 2.5% | 8.5% |
| Profit CAGR 5y | · | −3.2% |
PFE bills 1.3× the revenue of BMY, and BMY keeps more of each dollar of revenue as profit (14.6% against 12.5%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | BMY | PFE |
|---|---|---|
| FY2025 | $48.2B | $62.6B |
| FY2024 | $48.3B | $63.6B |
| FY2023 | $45.0B | $59.6B |
| FY2022 | $46.2B | $101.2B |
| FY2021 | $46.4B | $81.3B |
| FY2020 | $42.5B | $41.7B |
| FY2019 | $26.1B | $40.9B |
| FY2018 | $22.6B | $40.8B |
| FY2017 | $20.8B | $52.5B |
| FY2016 | $19.4B | $52.8B |
Bottom line
| Fiscal year | BMY | PFE |
|---|---|---|
| FY2025 | $7.1B | $7.8B |
| FY2024 | $-8.9B | $8.0B |
| FY2023 | $8.0B | $2.1B |
| FY2022 | $6.3B | $31.4B |
| FY2021 | $7.0B | $22.0B |
| FY2020 | $-9.0B | $9.2B |
| FY2019 | $3.4B | $16.0B |
| FY2018 | $4.9B | $11.2B |
| FY2017 | $1.0B | $21.3B |
| FY2016 | $4.5B | $7.2B |
19 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$14,385,000,000 | PFE |
| FY2024 | −$15,327,000,000 | PFE |
| FY2023 | −$14,547,000,000 | PFE |
| FY2022 | −$55,016,000,000 | PFE |
| FY2021 | −$34,903,000,000 | PFE |
| FY2020 | +$867,000,000 | BMY |
| FY2019 | −$14,760,000,000 | PFE |
| FY2018 | −$18,264,000,000 | PFE |
| FY2017 | −$31,770,000,000 | PFE |
| FY2016 | −$33,397,000,000 | PFE |
| FY2015 | −$32,291,000,000 | PFE |
| FY2014 | −$33,726,000,000 | PFE |
| FY2013 | −$35,199,000,000 | PFE |
| FY2012 | −$37,036,000,000 | PFE |
| FY2011 | −$39,791,000,000 | PFE |
| FY2010 | −$45,681,000,000 | PFE |
| FY2009 | −$30,461,000,000 | PFE |
| FY2008 | −$30,581,000,000 | PFE |
| FY2007 | −$32,801,000,000 | PFE |
The higher-revenue side has changed between BMY and PFE over this period. The gap has narrowed since the earliest year compared.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
19 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +2.2 pp | BMY |
| FY2024 | −31.2 pp | PFE |
| FY2023 | +14.2 pp | BMY |
| FY2022 | −17.3 pp | PFE |
| FY2021 | −12.0 pp | PFE |
| FY2020 | −43.2 pp | PFE |
| FY2019 | −26.0 pp | PFE |
| FY2018 | −5.5 pp | PFE |
| FY2017 | −35.9 pp | PFE |
| FY2016 | +9.5 pp | BMY |
| FY2015 | −4.5 pp | PFE |
| FY2014 | −5.7 pp | PFE |
| FY2013 | −27.0 pp | PFE |
| FY2012 | −12.5 pp | PFE |
| FY2011 | +8.3 pp | BMY |
| FY2010 | +10.4 pp | BMY |
| FY2009 | +45.5 pp | BMY |
| FY2008 | +18.4 pp | BMY |
| FY2007 | +1.8 pp | BMY |
The higher net margin has changed hands between BMY and PFE over this period.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BMY's net margin has been more volatile than PFE's over the 19 comparable fiscal years — 17.1 percentage points of standard deviation against 10.5.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between BMY and PFE over these 19 fiscal years — BMY led in 8 and PFE in 11.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
BMY's return on equity has been more volatile than PFE's over the 18 comparable fiscal years — 24.0 percentage points of standard deviation against 9.4.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between BMY and PFE over these 18 fiscal years — BMY led in 10 and PFE in 8.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.